Drug combinations show promising long-term survival in advanced cancers
Drug combinations show improved long-term survival in advanced thymic, endometrial, and kidney cancers.
Summary
Final results from the phase 2 PECATI clinical trial indicate that the combination of lenvatinib and pembrolizumab offers encouraging long-term survival for patients with previously treated advanced B3-thymoma and thymic carcinoma. Separately, an immunotherapy regimen of durvalumab and the PARP inhibitor olaparib has shown promising survival gains in advanced or recurrent endometrial cancer. Additionally, a phase 1/2 trial combining bevacizumab and pazopanib has significantly extended progression-free and overall survival for patients with the most common type of advanced kidney cancer.
Why it's important
These findings highlight the potential of drug combinations, including immunotherapy and targeted therapies, to improve long-term survival outcomes for patients with various advanced cancers, offering new hope and treatment strategies.
Key Points
- Drug combination for advanced thymic cancer
- Immunotherapy for advanced endometrial cancer
- Targeted therapies for advanced kidney cancer
- Long-term survival outcomes
Key Narratives
Based on positions and claims visible in the cited sources. Missing viewpoints are not inferred as full national or institutional perspectives.
Researchers from this institution presented trial results demonstrating that a durvalumab and olaparib regimen showed encouraging long-term survival in advanced or recurrent endometrial cancer.
This center led a phase 1/2 trial showing that combining bevacizumab and pazopanib significantly extends survival in patients with advanced kidney cancer.
Involved Entities
The University of Texas MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center
Sources (3)
Drug combination shows long-term survival in advanced thymic cancer
Final results from the phase 2 PECATI clinical trial demonstrate encouraging long-term survival outcomes with the combination of lenvatinib and pembrolizumab in patients with previously treated advanc
Drug combination delivers promising survival gains in advanced endometrial cancer
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, a
Targeted drug combination extends survival in advanced kidney cancer
Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progre
Keep exploring this topic
Browse more stories in English or search Knewvia for a custom brief on any topic.